• br Development of lorlatinib from crizotinib to a

  2024-02-07

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• Overexpression of AR can lead to sorbitol accumulation

  2024-02-07

  

  Overexpression of AR can lead to sorbitol accumulation, leading to diabetic complications (Ransohoff and Cardona, 2010). Therefore, AR is an important enzyme in the growth and development of organisms. With the aim of inhibiting the activity of AR in diabetic patients, screening for inhibitors and i

• A previous study showed that miR c

  2024-02-07

  

  A previous study showed that miR-200c is involved in glucose-mediated pathological processes (Zhang, Guan, & Jin, 2017). Glucose metabolism is critical for the growth and proliferation of both normal U 18666A and cancer cells, and reprogramming glucose metabolism now has been considered as a target

• The molecular mechanisms involved in the

  2024-02-06

  

  The molecular mechanisms involved in the pathogenesis of cholestatic pruritus remain unknown [45], [46]. Indeed, there has been an enormous effort at understanding the etiology of PBC-related pruritus, including work at the cellular and molecular level, but such efforts have not been translated into

• Demonstration of in vivo efficacy of

  2024-02-05

  

  Demonstration of in vivo efficacy of potential chemopreventive agents in animal models is necessary for their clinical development. Our present study provides experimental evidence that CuB 0.1μmol by oral administration (for 2weeks before the cancer cell injection, 5days per week) significantly inh

• Loss of expression or functional activity of

  2024-02-05

  

  Loss of expression or functional activity of cell adhesion is intricately related to advanced stages of tumour progression and invasiveness. Martin-Belmonte and Perez-Moreno recently mentioned that the deregulation of adhesion can alter tumourgenesis in the early stage. We have shown for the first t

• br ASK in Huntington s disease and other polyglutamine

  2024-02-05

  

  ASK1 in Huntington's disease and other polyglutamine diseases The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding regions of specific genes, leading to the production

• br Interaction between ASK and TRX Thioredoxins are small

  2024-02-05

  

  Interaction between ASK1 and TRX Thioredoxins are small (∼12kDa) dithiol oxidoreductases ubiquitously expressed in species ranging from plants to archaea and mammals. They perform various biological functions, such as reducing protein disulfide bonds, supplying reducing equivalents to redox BAY 4

• Epiberberine Secondly leptin has been shown to enhance aroma

  2024-02-05

  

  Secondly, leptin has been shown to enhance aromatase mRNA expression, aromatase content and its enzymatic activity in epithelial breast cancer Epiberberine by inducing promoters II and I.3 via an enhanced binding of transcription activator protein 1 (AP-1) complex to specific DNA sites in the promo

• As regards LEPR Sun et al

  2024-02-05

  

  As regards LEPR, Sun et al. showed that the rs1137101-223A > G polymorphism influences the effectiveness of simvastatin on plasma HDL-C levels in CHD patients [35]. In accordance with the results of García-Bermúdez et al., however, no such an association exists between leptin rs2167270 (G > A) polym

• br Special report Financial and

  2024-02-05

  

  Special report – Financial and personal benefits of early diagnosis Acknowledgments The Alzheimer’s Association acknowledges the contributions of Joseph Gaugler, Ph.D., Bryan James, Ph.D., Tricia Johnson, Ph.D., Allison Marin, Ph.D., and Jennifer Weuve, M.P.H., Sc.D., in the preparation of 201

• Previous studies to investigate the functions

  2024-02-05

  

  Previous studies to investigate the functions of AHR in Treg Rottlerin have employed a loss-of-function approach, using AHR complete-null mice, or a gain-of-function approach by ligand administration. However, these approaches may confound the interpretation of the results. For example, the broad ex

• Additionally regulation of GPCR heteromerization by

  2024-02-05

  

  Additionally, regulation of GPCR heteromerization by specific ligands may depend not only on the affinity of ligands for receptors, but also on presence of different interacting proteins co-localizing with the receptors in the specific cell, which may induce some conformational changes and contribut

• The assay performance was estimated using

  2024-02-05

  

  The assay performance was estimated using Z′-factors (plotted in Fig. 2A) according to Zhang et al. calculated for each plate comparing positive (in the absence of an inhibitor) and negative controls (in the presence of an AdK inhibitor). The mean Z′-factor±SD was determined to be 0.7±0.1, indicativ

• Previous reports indicate that the expression of AChRs and

  2024-02-04

  

  Previous reports indicate that the expression of AChRs and their clustering on myotubes are critical factors required to induce contacts on muscle fibers in a natural biological system [14], [15], [16], [17], [18], [19]. For instance, in NMJ development in the mouse, AChRs are pre-patterned at sites

14768 records 222/985 page Previous Next First page 上5页 221222223224225 下5页 Last page